Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus
Author
dc.contributor.author
Codner Dujovne, Ethel
Author
dc.contributor.author
Escobar-Morreale, Héctor F.
Admission date
dc.date.accessioned
2019-03-11T12:53:59Z
Available date
dc.date.available
2019-03-11T12:53:59Z
Publication date
dc.date.issued
2007
Cita de ítem
dc.identifier.citation
Journal of Clinical Endocrinology and Metabolism, Volumen 92, Issue 4, 2018, Pages 1209-1216
Identifier
dc.identifier.issn
0021972X
Identifier
dc.identifier.issn
0021972X
Identifier
dc.identifier.other
10.1210/jc.2006-2641
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164307
Abstract
dc.description.abstract
Context: At present, women with type 1 diabetes (DM1) are being treated with supraphysiological doses of exogenous insulin with the aim of providing a strict metabolic control, thereby avoiding the long-term complications of this disease. Wehypothesized that PCOS would be especially prevalent in DM1, as might happen in any condition in which the ovary and the adrenals are exposed to excessive insulin concentrations. As will be seen in the present review, androgen excess and PCOS are very frequent complaints in women with DM1, yet nowadays hyperandrogenism is seldom diagnosed in these patients. Evidence Acquisition: We conducted a systematic review of all the published studies addressing hyperandrogenic symptoms in women with DM1, identified through the Entrez-PubMed search engine, followed by a comprehensive review of the pathophysiology and clinical and laboratory features of PCOS in women with DM1. Evidence Synthesis: The prevalence of PCOS in adult women with DM1 is 12-18, 40, and 3